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The rescue of DCD rodent livers grafts: Is there HOPE?
To the Editor:
It is with great interest that we have read the article of Schlegel
et al. [1] on normothermicmachine perfusion (NMP) vs. hypother-
mic oxygenated perfusion (HOPE) to rescue rodent liver grafts,
suffering from extended warm ischemia. In this study, a compar-
ison was made between the ability of NMP and HOPE to rescue
DCD rodent liver grafts with prolonged warm ischemia of 30
and 60 min. Grafts were subjected to ex vivo reperfusion using
an isolated perfused rat liver model (IPRL) and orthotopic liver
transplantation (OLT). The authors claim superiority of HOPE to
rescue rat liver grafts with extended warm ischemia time.
This is an interesting ﬁnding, which is explained by the
authors as the result of downregulation of several physiological
processes, which protect grafts from oxidative stress following
transplantation. However, these differences in outcome could
very well be affected by different methods in both groups, which,
to our opinion, the authors do not address in their publication.
1. In NMP, the perfusate composition of Brockmann et al. [2] was
chosen, instead of the composition described by Op den
Dries et al. The aim of NMP is to preserve a metabolically fully
active liver and to resemble physiological circumstances [3].
Unpublished data from our institution show metabolic
dysfunction as key mechanism underlying graft failure upon
kidney transplantation. Energy supply during NMP might not
be sufﬁcient to correspond to the physiological setting, and
speciﬁc demands for liver grafts are not studied yet. Regarding
metabolic dysfunction, NMP might not be optimal in this
experiment.
2. The authors show that DCD grafts are more subject to
ischemic damage, encountered during the ﬁrst warm ischemic
period. We assume that graft oxygenation was sufﬁcient,
however, since the perfusate contained only a haematocrit of
14–16%, are the authors certain that the right amount of
oxygen was added to the perfusate, since Op den Dries et al.
previously chose supernormal oxygen levels [3]. The oxygen
level was targeted at 40–50 kPa in the NMP group and at
50–60 kPa in the HOPE group. No pH and lactate measurement
levels were reported in this publication.
3. HOPE was performed only through the portal vein and NMP
through both the portal vein and hepatic artery, when OLT
was performed with only portal anastomosis. May the arterial
ﬂow during NMP have injured the liver graft? Could it be that
the difference in outcome is caused by this method?
We have to be careful to extrapolate rodent transplantation
experiment results into clinical transplantation in humans; no
UW solution ﬂush was performed in these experiments. We
would like to congratulate the authors on their achievements,
but HOPE these questions could be addressed by the authors
and are looking forward to discuss these promising techniques.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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Reply to: ‘‘The rescue of DCD rodent livers grafts: Is there HOPE?’’
To the Editor:
We read with great interest the letter by Kopp et al. regarding
our study on machine perfusion of rat livers, donated after car-
diac death (DCD). Our goal was to compare the two main liver
perfusion techniques, normothermic (NMP) and hypothermic
oxygenated perfusion (HOPE) in terms of liver function and
injury in a transplant model, closely adapted to the clinical
situation [1].
We are pleased to discuss the points raised by the letter from
the Leiden’s group. The ﬁrst question targets on the perfusate com-
positionused in thenormothermic experiments.Wehave carefully
chosen a perfusate for NMP experiments that is closely adapted to
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and showed a comparable amount of injury in terms of AST
release, pH, lactate and bile production (Supplementary
Fig. 1). In addition, as healthy controls demonstrated good
function after normothermic dual perfusion and transplanta-
tion, we assume no increased injury by the dual perfusion
technique. Finally, we would like to state that all livers were
ﬂushed with UW solution after initial ﬂush with heparinized
saline (see Materials and methods).
In summary, we would like to thank the authors for their
valuable questions and comments. We agree that human trials
are needed to discover the impact of both machine perfusion
techniques. We have recently initiated a multicentre randomized
trial on HOPE for human livers transplants, donated after brain
death (DBD) (www.hope-liver.com).
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jhep.2014.
11.013.
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current leaders in the ﬁeld. For normothermic perfusion experi-
ments with diluted blood, we used a perfusate described by the
group of Peter Friend [2], who demonstrated very recently the ﬁrst
worldwide application of normothermic oxygenated perfusion in
twenty human livers (reported at the WTC 2014, San Francisco).
Second, for experiments with a leukocyte and platelet-depleted
perfusate, we used the perfusate described by the group of Robert
Porte [3]. Both groups report a haematocrit of approximately 20%,
insulin, heparin and nutritions were similarly as in our experi-
ments. Adding of Williams E medium in normothermic experi-
ments is based on recent experiments by Op den Dries et al. in
rats [4]. Both perfusates have been tested initially in healthy nor-
mal rat livers (no injury group) and achievedminimal AST release,
sufﬁcient bile ﬂow, tissueATP and100%animal survival, thus dem-
onstrating sufﬁcient energy supply during normothermic perfu-
sion experiments (Fig. 1).
The second question is on oxygen levels during normothermic
perfusion. Op den Dries et al. reported 50–70 kPa for human liv-
ers, while Brockmann et al. perfused with 15–20 kPa. We per-
fused rat livers with 50 kPa, as oxygen measurements at the
liver outﬂow conﬁrmed by far sufﬁcient oxygenation in all exper-
iments with this degree of oxygenation, also demonstrated by
stable pH and lactate (Supplementary Fig. 1).
The third question targets on the different perfusion routes
in HOPE and in normothermic experiments (portal vein only vs.
dual perfusion). We have also performed normothermic perfu-
sion in rat livers (no injury and DCD) through the portal vein
only. These grafts were compared to dually perfused rat liversSham
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Fig. 1. Healthy liver grafts during normothermic perfusion using different perfusates. (This ﬁgure appears in color on the web.)
740 Journal of Hepatology 2015 vol. 62 j 739–752
References
[1] Schlegel A, Kron P, Graf R, Dutkowski P, Clavien PA. Warm vs. cold perfusion
technique to rescue rodent liver grafts. J Hepatol 2014;61:1267–1275.
[2] Brockmann J, Reddy S, Coussios C, Pigott D, Guirriero D, Hughes D, et al.
Normothermic perfusion: a new paradigm for organ preservation. Ann Surg
2009;250:1–6.
[3] Op den Dries S, Karimian N, Sutton ME, Westerkamp AC, Nijsten MW, Gouw
AS, et al. Ex vivo normothermic machine perfusion and viability testing of
discarded human donor livers. Am J Transplant 2013;13:1327–1335.
[4] Op den Dries, Karimian N, Sutton ME, Kuipers M, Wiersema-Buist J, Ottens PJ,
et al. Machine perfusion reduces Bile duct injury and improves biliary
epithelial function in rat donor livers, in Studies on etiology and the
protective Role of machine perfusion, Chapter 9, page 128–146 [Ph.D. thesis];
2013, submitted for publication.
Andrea Schlegel
Philipp Dutkowski
Pierre-Alain Clavien⇑
Swiss Hepato-Pancreatico-Biliary and Transplant Center,
Department of Surgery and Transplantation,
University Hospital Zürich, Zurich, Switzerland⇑Corresponding author.
E-mail address: clavien@access.uzh.ch
A cut-off serum creatinine value of 1.5 mg/dl for AKI – To be
or not to be
To the Editor:
Acute renal failure (ARF) is a common problem in patients with
decompensated cirrhosis and ascites [1]. Traditionally, the diag-
nosis of ARF is made using the conventional criteria of a 50%
increase in serum creatinine with the ﬁnal serum creatinine
reaching P1.5 mg/dl [2]. More recently, it has been recognized
in non-cirrhotic patients that smaller increases in serum creati-
nine also have a negative impact on survival [3]. This has led var-
ious learned societies to re-deﬁne ARF as acute kidney injury
(AKI), incorporating even small changes in serum creatinine either
in absolute or percentage terms in the diagnostic criteria [4–6].
The degree of AKI severity is also deﬁned by stages [4–6]. The
most commonly reported classiﬁcation used to diagnose AKI is
that of the Acute Kidney Injury Network (AKIN), which set forth
speciﬁc serum creatinine and urine output changes to deﬁne
stages of AKI, without setting a ﬁxed serum creatinine level in
its diagnostic criteria [5]. Comparison of results from various
studies in patients with cirrhosis has been difﬁcult, as these stud-
ies assessed cirrhotic patients of various disease severities, in dif-
ferent hospital settings, using differentmethodologies to calculate
the change in serum creatinine [7–9]. Emerging from these
studies are the ﬁndings that both the severity of AKI, as well as
the progression of AKI have a negative impact on patient survival.
In two recent articles by Fagundes et al. [10], and Piano et al. [11],
published in the Journal of Hepatology, which evaluated the impact
of AKI on short-term mortality in patients with decompensated
cirrhosis, admitted to the hospital for various reasons, similar
trends were reported. Both studies incorporated parts of the AKIN
criteria using the conventional criteria for the diagnosis of AKI.
Fagundes et al. found that patients with stage 1 AKI (increase in
serum creatinine by either 0.3 mg/dl or by 50% irrespective of
the ﬁnal serum creatinine) and peak serum creatinine of
61.5 mg/dl had a very good survival, similar to that of non-AKI
patients [10]. Piano et al. found that the conventional diagnostic
criteria, using a cut-off serum creatinine of 1.5 mg/dl was better
than the AKIN criteria in the prediction of survival. This is not
surprising, as the conventional diagnostic criteria tend to select
out patients with more severe kidney injury. Furthermore, a
serum creatinine of P1.5 mg/dl was able to predict progression
of AKI [11]. Based on these two studies, Fagundes et al. proposed
instituting a new classiﬁcation of AKI in cirrhosis, separating cir-
rhotic patients with AKI into 3 subgroups: (i) stage 1 with a ﬁnal
serum creatinine of61.5 mg/dl, (ii) stage 1 with a ﬁnal serum cre-
atinine of >1.5 mg/dl, and (iii) combined stages 2 and 3. Piano et al.
suggested that future interventional trials should incorporate
certain aspects of the AKIN criteria, namely, small increment of
0.3 mg/dl in serum creatinine and staging, to allow assessment
of progression, while maintaining the conventional diagnostic
criteria, requiring a minimum serum creatinine ofP1.5 mg/dl.
Therefore, these two studies seem to suggest a serum creati-
nine cut-off value of 1.5 mg/dl is important in the management
of AKI and the prediction of patient outcome in cirrhosis. These
studies also imply that AKI episodes with a lower peak serum cre-
atinine may not be clinically important., and may not require
intervention However, as Thalheimer and Burroughs pointed
out, AKI with a peak serum creatinine of <1.5 mg/dl is not a
benign condition [12]. One has to emphasize that the above
two studies were designed speciﬁcally to evaluate the impact of
AKI on short-term survival in a very speciﬁc population of cir-
rhotic patients, namely hospitalized cirrhotic patients. They did
not set out to evaluate the impact of AKI on other events that
could be important in the natural history of cirrhosis, such as
recurrence of AKI, the development of future complications, or
future hospitalizations. In light of the marked variation in base-
line creatinine between cirrhotic patients, using a speciﬁc serum
creatinine cut-off value could potentially result in the late diag-
nosis of AKI, and delay interventions. In a totally different setting
of outpatient decompensated cirrhotics, Tsien et al. reported that
patients with AKI, deﬁned as a rise in serum creatinine by either
0.3 mg/dl within <48 h or an increase of 50% from a stable value
in the previous 6 months, and a mean peak serum creatinine
within the normal laboratory range had a worse prognosis com-
pared to those without AKI when followed for 12 months [13]. In
another cohort of hospitalized decompensated cirrhotic patients
with infection (n = 337) [14], a higher percentage of those who
developed AKI (n = 166) died within 30 days, despite receiving
the standard of care for their AKI plus prompt antibiotic treat-
ment. Re-analysis of the data showed that of the 166 patients
who developed AKI, there were 31 patients whose peak serum
creatinine was 61.5 mg/dl (group A), and 135 patients whose
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